Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial

AbstractObjective: To evaluate, post hoc, the efficacy and safety of abaloparatide by degree of renal impairment.Methods: ACTIVE was a phase 3, 18-month, randomized, double-blind, active-comparator...